• Publications
  • Influence
ESC Guidelines on the Diagnosis and Treatment of Peripheral Artery Diseases
Endorsed by: the European Stroke Organisation (ESO) Authors/Task Force Members: Michal Tendera (Chairperson) (Poland), Victor Aboyans (Co-Chairperson) (France), Marie-Louise Bartelink (TheExpand
  • 1,316
  • 67
  • Open Access
Perindopril for elderly people with chronic heart failure: the PEP‐CHF study
The prevalence of chronic heart failure (CHF) rises with increasing age, from <1% in those below 65 years of age to > 5% in those over 65 years of age and is a major cause of morbidity and mortalityExpand
  • 842
  • 47
Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology.
Guidelines and Expert Consensus documents aim to present all the relevant evidence on a particular issue in order to help physicians to weigh the benefits and risks of a particular diagnostic orExpand
  • 1,162
  • 45
  • Open Access
Effect of carvedilol on survival in severe chronic heart failure.
BACKGROUND Beta-blocking agents reduce the risk of hospitalization and death in patients with mild-to-moderate heart failure, but little is known about their effects in severe heart failure. Expand
  • 2,639
  • 44
  • Open Access
Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial
BACKGROUND Ivabradine specifically inhibits the I(f) current in the sinoatrial node to lower heart rate, without affecting other aspects of cardiac function. We aimed to test whether lowering theExpand
  • 893
  • 34
Ivabradine in stable coronary artery disease without clinical heart failure.
BACKGROUND An elevated heart rate is an established marker of cardiovascular risk. Previous analyses have suggested that ivabradine, a heart-rate-reducing agent, may improve outcomes in patients withExpand
  • 316
  • 26
  • Open Access
Resting heart rate in cardiovascular disease.
The importance of resting heart rate (HR) as a prognostic factor and potential therapeutic target is not yet generally accepted. Recent large epidemiologic studies have confirmed earlier studies thatExpand
  • 809
  • 20
Facilitated PCI in patients with ST-elevation myocardial infarction.
BACKGROUND We hypothesized that percutaneous coronary intervention (PCI) preceded by early treatment with abciximab plus half-dose reteplase (combination-facilitated PCI) or with abciximab aloneExpand
  • 470
  • 20
  • Open Access
Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial
BACKGROUND The BEAUTIFUL study assessed the morbidity and mortality benefits of the heart rate-lowering agent ivabradine. The placebo arm of the BEAUTIFUL trial was a large cohort of patients withExpand
  • 688
  • 19